Business Description
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Business History
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -11.11
Total Equity: $2.58B
Shares: 36,753,751
Total Debt: $54.86M
Cash: $249.73M
EBITDA: -$378.16M
Total Debt: $54.86M
Cash: $249.73M
Revenue: $147.17M
Shares: 36,753,751
Revenue: $147.17M
Revenue: $147.17M
Revenue: $147.17M
Total Equity: $2.58B
Tax Rate: 23.6%
Equity: $2.58B
Total Debt: $54.86M
Cash: $249.73M
Current Liabilities: $79.67M
Long-Term Debt: $43.15M
Total Debt: $54.86M
Total Equity: $2.58B
Shares: 36,753,751
Shares: 36,753,751
CapEx: -$909,000
Shares: 36,753,751
Stock Price: $69.11
Net Income: -$408.35M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jul 3, 2026 4:52am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $14.6M | $55.6M | $93.1M | $125.6M | $147.2M |
| Cost of Revenue | $114.6M | $172.0M | $188.7M | $203.6M | $209.7M |
| Gross Profit | -$100.0M | -$116.4M | -$95.6M | -$78.0M | -$62.6M |
| Operating Expenses | $1.2B | $5.3B | $1.4B | $2.1B | $471.6M |
| Operating Income | -$1.3B | -$5.4B | -$1.5B | -$2.2B | -$534.2M |
| Net Income | -$1.2B | -$5.4B | -$1.5B | -$2.0B | -$408.4M |
| EBITDA | -$1.2B | -$587.7M | -$638.2M | -$610.2M | -$378.2M |
| EPS | $-40.18 | $-173.87 | $-47.20 | $-63.54 | $-11.11 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 3, 2026 4:52am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $221.2M | $241.6M | $97.3M | $214.2M | $249.7M |
| Total Current Assets | $242.7M | $295.6M | $156.1M | $819.9M | $953.8M |
| Total Assets | $9.7B | $5.6B | $4.6B | $3.0B | $2.9B |
| Current Liabilities | $97.9M | $134.9M | $163.6M | $76.9M | $79.7M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $43.1M |
| Total Liabilities | $307.4M | $955.9M | $910.7M | $479.9M | $344.2M |
| Total Equity | $9.4B | $4.6B | $3.6B | $2.5B | $2.6B |
| Retained Earnings | -$911.5M | -$6.3B | -$7.8B | -$9.8B | -$10.2B |
Cash Flow (Annual)
Last updated: Jul 3, 2026 4:52am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$688.1M | -$561.3M | -$595.8M | -$577.2M | -$299.0M |
| Capital Expenditure | -$69.9M | -$22.9M | -$12.9M | -$5.2M | $-909,000 |
| Free Cash Flow | -$758.1M | -$584.2M | -$608.7M | -$582.4M | -$299.0M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $-170,000 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$143.2M | $20.1M | -$144.6M | $116.1M | $39.1M |
Analyst Estimates (Annual)
Last updated: Jul 3, 2026 4:52am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$223.5M $202.6M – $247.4M
|
$286.5M $286.5M – $286.5M
|
$377.7M $352.5M – $407.7M
|
$492.5M $459.6M – $531.6M
|
| EBITDA |
-$223.5M -$247.4M – -$202.6M
|
-$286.5M -$286.5M – -$286.5M
|
-$377.7M -$407.7M – -$352.5M
|
-$492.5M -$531.6M – -$459.6M
|
| Net Income |
-$389.1M -$404.5M – -$373.7M
|
-$442.1M -$489.8M – -$292.3M
|
-$388.6M -$428.8M – -$355.0M
|
-$351.5M -$387.8M – -$321.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 3, 2026 4:52am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +280.2% | +67.6% | +34.9% | +17.2% |
| Gross Profit Growth | -16.4% | +17.9% | +18.4% | +19.8% |
| Operating Income Growth | -330.2% | +72.2% | -44.5% | +75.6% |
| Net Income Growth | -332.7% | +72.9% | -38.3% | +79.9% |
| EBITDA Growth | +51.3% | -8.6% | +4.4% | +38.0% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-18 | CHASE WILLIAM J | A-Award | 5,491.00 | $63.74 | $349,996 |
| 2026-06-18 | MIZELL STEVEN | A-Award | 5,491.00 | $63.74 | $349,996 |
| 2026-06-18 | SUMME GREGORY L | A-Award | 5,491.00 | $63.74 | $349,996 |
| 2026-06-18 | Krevans Sarah | A-Award | 5,491.00 | $63.74 | $349,996 |
| 2026-06-04 | Partridge Andrew John | S-Sale | 1,491.00 | $61.08 | $91,070 |
| 2026-06-03 | Ofman Joshua J. | A-Award | 3,154.00 | $61.13 | $192,804 |
| 2026-06-01 | Ofman Joshua J. | A-Award | 27,901.00 | $64.40 | $1.8M |
| 2026-06-01 | Partridge Andrew John | 0.00 | $0.00 | $0 | |
| 2026-04-15 | MIZELL STEVEN | A-Award | 396.00 | $49.79 | $19,717 |
| 2026-04-15 | CHASE WILLIAM J | A-Award | 408.00 | $49.79 | $20,314 |
| 2026-04-15 | SUMME GREGORY L | A-Award | 631.00 | $49.79 | $31,417 |
| 2026-04-08 | Freidin Aaron | S-Sale | 45,806.00 | $49.92 | $2.3M |
| 2026-04-08 | RAGUSA ROBERT P | S-Sale | 123,502.00 | $49.92 | $6.2M |
| 2026-04-08 | Ofman Joshua J. | S-Sale | 61,665.00 | $49.92 | $3.1M |
| 2026-03-05 | Freidin Aaron | S-Sale | 655.00 | $53.01 | $34,722 |
| 2026-03-09 | Freidin Aaron | S-Sale | 2,407.00 | $47.93 | $115,368 |
| 2026-03-09 | Freidin Aaron | S-Sale | 85.00 | $46.74 | $3,973 |
| 2026-03-05 | Ofman Joshua J. | S-Sale | 690.00 | $53.01 | $36,577 |
| 2026-03-09 | Ofman Joshua J. | S-Sale | 2,836.00 | $47.93 | $135,929 |
| 2026-03-09 | Ofman Joshua J. | S-Sale | 101.00 | $46.74 | $4,721 |
Narrative Economics
market-narrative step).